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Abstract
Probiotics are live microorganisms, which confer health benefits on host when admin-
istered in adequate amounts. Probiotics exert their beneficial effects by maintenance 
flora healthy, enhancement of mucosal barrier integrity and  modulation of immune 
responses. Antimicrobial substances including bacteriocins, hydrogen peroxide, organic 
acids, and short-chain fatty acids (SCFAs) produced by probiotics allow them to inhibit 
mucosal and epithelial adherence of pathogens and compete for limiting resources, thus 
suppress the growth of bacterial and fungal pathogens. Probiotics effect the coloniza-
tion of fungal pathogen Candida to host surfaces, suppress Candida growth and biofilm 
development in vitro. Clinical results have shown that some probiotics can reduce oral, 
vaginal, and enteric colonization of Candida, alleviate clinical signs and symptoms, and 
potentially reduce the incidence of invasive fungal infection. Therefore, probiotics may 
be potential antifungals for prevention and treatment of candidiasis.
Keywords: probiotics, mechanism of action, antimicrobial activity, candidiasis, safety
1. Introduction
Probiotics are “live microorganisms that, when administered in adequate amounts, confer 
a health benefit on the host,” which was defined by the Food and Drug Organization of the 
United Nations (FAO) and World Health Organization (WHO) [1–3]. Probiotics should have 
some fundamental characteristics, such as human origin, nonpathogenic in nature, resistance 
to destruction by technical processing, acid and bile tolerances, adequate adherence and colo-
nization on epithelial surfaces, antagonistic activity against pathogens, regulation of immune 
response, and influence human metabolic activities [4–7].
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the t rms of the Crea ive
Comm ns Attribution Lic nse (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Bacteria belonging to the genera Lactobacillus and Bifidobacterium are the most frequently used 
probiotics. Besides, Enterococcus, Streptococcus, Saccharomyces, and Bacillus are also commonly 
used probiotics (representative species are listed in Table 1). The administration of probiot-
ics has been confirmed as an alternative biological approach to combat bacterial and fungal 
pathogens in the oral cavity, GI tract, and urogenital system [4, 5, 7–14]. It has been reported 
that probiotics could reduce Candida, which cause fungal infections in different organ systems 
of the human body and prevent bacterial infectious diseases [9, 10, 15]. Probiotics were capa-
ble of preventing cancers [16], modulating blood pressure [17, 18], and repressing cholesterol 
levels [19]. Recently, species of Akkermansia muciniphila, Eubacterium hallii, and Faecalibacterium 
prausnitzii are identified as new potential probiotics because of their great benefits to the micro-
bial metabolic networks and human health, especially the effects on correcting the imbalance 
of gut microbiota composition [7, 20–22]. A combination of probiotics with traditional treat-
ment has been thought to be a potential approach for treatment of certain diseases.
It is noteworthy that health benefits of probiotic bacteria are strain specific, which cannot 
be generalized to other strains, not even the same species, although some properties may be 
common for different strains because of the similarities in the metabolism of ecological func-
tionality [5, 6]. Thus, the selection of certain probiotics for therapeutic purposes should be 
targeted for specific pathogens. Probiotics effects are dose specific [5, 6]. It has been suggested 
that a daily intake of 106–109 colony-forming units (CFUs) of probiotic microorganisms is the 
minimum effective dose for therapeutic purposes [5, 6, 8].
A number of probiotics are currently commercially available, and they have been catego-
rized into single-strain or multi-strain/multispecies products [7, 23, 24]. Multi-strain/mul-
tispecies probiotics exhibited better effects than single-strain probiotics. The multispecies 
probiotic consortium VSL#3 (Streptococcus thermophilus, Eubacterium faecium, Bifidobacterium 
breve, Bifidobacterium infantis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus 
Genera Species
Lactobacillus Lactobacillus rhamnosus, Lactobacillus casei, Lactobacillus plantarum, Lactobacillus acidophilus, 
Lactobacillus reuteri, Lactobacillus paracasei, Lactobacillus sporogenes, Lactobacillus lactis, Lactobacillus 
helveticus, and Lactobacillus fermentium
Lactococcus Lactococcus lactis, Lactococcus lactis subsp. lactis, Lactococcus lactis subsp. diacetylactis, and 
Lactococcus Lactis subsp. cremoris
Bifidobacterium Bifidobacterium longum, Bifidobacterium bifidum, Bifidobacterium bifidus, and Bifidobacterium lactis
Enterococcus Enterococcus faecalis and Enterococcus faecium
Saccharomyces Saccharomyces cerevisiae and Saccharomyces boulardii
Streptococcus Streptococcus thermophiles
Bacillus Bacillus coagulans and Bacillus subtilis
Others Akkermansia muciniphila, Eubacterium hallii, and Faecalibacterium prausnitzii
Table 1. Representative microbe commonly considered as probiotics.
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plantarum, Lactobacillus casei, and Lactobacillus delbrueckii subsp. bulgaricus) was proven more 
effective than single-strain probiotics for the treatment of ulcerative colitis [23]. The multispe-
cies probiotic consortium, Ecologic AAD (Bifidobacterium bifidum W23, Bifidobacterium lactis 
W18, Bifidobacterium longum W51, Enterococcus faecium W54, Lactobacillus acidophilus W37 and 
W55, Lactobacillus paracasei W72, Lactobacillus plantarum W62, Lactobacillus rhamnosus W71, and 
Lactobacillus salivarius W24), combined with amoxicillin, could reduce diarrhea-like bowel 
movements, while the single strain could not [25]. Thus, the combination-specific probiotic 
effects from diverse strains can lead to synergistic effects.
Among the most frequently used probiotics, the genera Lactobacillus, Bifidobacterium, 
Lactococcus, and Saccharomyces have been included in the category of “generally regarded as 
safe” (GRAS) [4, 6]; however, other probiotic organisms such as Enterococcus, Bacillus, and 
Streptococcus are not generally regarded as safe. Since probiotics have been applied in food 
production, disease treatment, and others, it is important to undergo safety evaluation of 
probiotics before human consumption.
In this chapter, we briefly review the mechanisms of action of probiotics, the safety concern of 
probiotics, and their potentials for prevention and treatment of diseases. Here, we discuss the 
application of probiotics in the fungal Candida-infected and invasion candidiasis.
2. Probiotics mechanism of action
Probiotics mechanism of action is with important differences among different species and 
strain, examples are listed in Table 2.
2.1. Maintenance flora healthy by reduction the growth and colonization  
of pathogens
The ability of probiotics to establish in the gastrointestinal (GI) tract, maintain flora healthy, 
and reduce the growth of pathogens and colonization is enhanced by their ability to eliminate 
competitors. Probiotic strains release different antimicrobial molecules such as organic acids, 
hydrogen peroxide (Н
2
О
2
), and antimicrobial peptide bacteriocins into the intestinal environ-
ment to limit the growth of bacterial and fungal pathogens [6, 39–43].
Lactic acid and acetic acid are the main metabolites formed by lactic acid bacteria (LAB). Both 
lactic acid and acetic acid could result in acidity environment and thus inhibit the growth of 
various microorganisms. Acetic acid has a broader spectrum of antimicrobial activity when 
compared to lactic acid. Moreover, it is known that a synergistic effect exists between the two 
acids: mixtures of acetic and lactic acids suppress the growth of the pathogenic enteric bacte-
rium Salmonella typhimurium [44].
LAB can also produce Н
2
О
2
, the antimicrobial activity of which is linked to the strong oxi-
dizing effect. Hydrogen peroxide showed a bactericidal effect on most pathogens when in 
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 combination with lactoperoxidase-thiocyanate milk system [45]. L. johnsonii NCC933 and 
L. gasseri KS120.1 killed enteric uropathogenic and vaginosis-associated pathogens due to the 
production of lactic acid and hydrogen peroxide [46].
Mechanism of 
action
Probiotics Study outcomes References
Maintenance 
flora healthy 
by reduction 
the growth and 
colonization of  
pathogens
L. rhamnosus GG, L. casei Shirota, 
L. reuteri SD2112 and L. brevis 
CD2
L. rhamnosus GG showed the strongest 
inhibitory  activity in fructose and glucose 
medium against C. albicans, followed by L. casei 
Shirota, L. reuteri SD2112 and L. brevis CD2
[26]
L. plantarum, commercial 
preparation LactoLevure®
Increased survival of mice infected by 
multidrug resistant P. aeruginosa and E. coli
[27]
B. breve, L. casei (randomized 
controlled trial, RCT)
Levels of beneficial organic acids significantly 
increased in the gut, and the incidences 
of infectious (pneumonia and bacteremia) 
complications were significantly lower in the 
probiotic group
[32]
Synbiotic (Lactobacillus, 
Bifidobacterium, and 
galactooligosaccharides) for 
8 weeks (RCT)
Acetic acid concentration significantly increased 
(100 times), pH value decreased, Gram-
negative rod (1/10) in the gut decreased, and 
P. aeruginosa decreased in the probiotic group
[33]
Multi-strain synbiotic for 7 days 
(RCT)
Synbiotic group had lower pathogenic bacteria 
(43% versus 75%) and multiple organisms 
(39% versus 75%) in nasogastric aspirates than 
controls
[34]
B. lactis Bb12 for 7–21 days (RCT) Probiotic group had great higher counts of 
Bifidobacterium (P = 0.001) and lower counts of 
Enterobacteriaceae (P = 0.015) and Clostridium 
spp. (P = 0.014) than in placebo group
[35]
L. casei subsp. rhamnosus for 
6 weeks (RCT)
Colonization of Candida in gut was reduced in 
probiotic group (P = 0.01)
[28]
Enhancement of 
mucosal barrier 
integrity
L. plantarum 299v for 8 days 
(RCT)
Bacterial translocation in mesenteric lymph 
nodes and liver was reduced to 0 and 12%, 
respectively
[29]
Microencapsulated Bifidobacteria Bacterial translocation to mesenteric 
lymph nodes was reduced by encapsulated 
Bifidobacteria (P < 0.05)
[30]
VSL#3 (RCT) Decreased incidence of bacterial translocation 
in VSL#3 group than in water group (8% versus 
50%; P = 0.03)
[31]
Immune 
modulation
VSL#3 (Lactobacillus, 
Bifidobacterium, and 
S. thermophilus) for 7 days (RCT)
Reduced acute physiology and chronic health 
evaluation II score; reduced sequential organ 
failure assessment, IL-6, procalcitonin, and 
protein
[36]
L. plantarum 299v (RCT) Late attenuating effect (after 15 days), serum 
IL-6 levels reduced
[37]
Table 2. Mechanism of action of probiotics.
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Bacteriocins are ribosomally synthesized antimicrobial peptides, which have broad spectrum of 
inhibitory effect against Gram-positive and Gram-negative bacteria, viruses, and fungi [47–50]. 
L. plantarum 2.9, a bacteriocinogenic strain, inhibited a set of foodborne pathogens including 
B. cereus, E. coli O157:H7, and S. enterica [51]. Bacteriocin-producing strains identified in our 
lab, e.g., L. plantarum ZJ316, L. plantarum LZ95, L. plantarum ZJ008, and L.  plantarum ZJ005, 
showed antimicrobial activity against various pathogens in vitro such as S. aureus, E. coli, 
S. enterica, L. monocytogenes, and C. albicans [42, 52–54].
2.2. Enhancement of mucosal barrier integrity
Probiotics have been shown to improve barrier function and the mechanisms of barrier func-
tion including alteration of tight junction protein expression and/or localization, induction of 
mucus secretion, increased production of cytoprotective molecules such as heat-shock pro-
teins, inhibition of apoptosis of epithelial cells, and promoting cell survival [29, 55, 56]. They 
compete with pathogens and prevent their invasion through the epithelium by the ability of 
adherence to the intestinal epithelium and mucus. L. plantarum has been shown to enhance 
mucosal barrier by adhering to the mucosal membrane and reducing Gram-negative bacteria 
[29]. Probiotics also compete for limiting resources, thus suppressing the growth of bacterial 
and fungal pathogens. The probiotic E. coli Nissle 1917 is able to effectively take up multiple 
limited environmental irons and simultaneously competitively inhibit the growth of other 
intestinal microbes and pathogens [57].
Furthermore, butyrate, a short-chain fatty acid (SCFA), could reduce bacterial translocation, 
improve the organization of tight junctions, modulate intestinal motility in addition to being 
an energy source for colonocytes, and maintain the integrity of the intestinal epithelium 
[29–31, 58–60]. E. hallii is an important anaerobic butyrate producer resident in our gut, which 
influences the intestinal metabolic balance and enhances the host-gut microbiota homeostasis 
[61]. Thus, the administration of probiotics with butyrate-producing bacteria, in particular, 
could be an effective way to achieve health benefits.
2.3. Immune modulation
Probiotics are reported to enhance phagocytic activity of granulocytes and cytokine excre-
tion in lymphocytes, increase immunoglobulin-secreting cells, and attenuate inflammasome 
activation. They are able to affect cells involved in immune responses, including epithelial 
cells, dendritic cells (DCs), T cells, regulatory T (Treg) cells, monocytes/macrophages, immu-
noglobulin A (IgA)-producing B cells, and natural killer cells [62, 63].
Probiotic bacteria have an effect on intestinal DCs, which have the ability to recognize and 
respond to different bacteria by linking the innate immune system to the adaptive immune 
response and to develop T- and B-cell responses. Badia et al. found that the immunomodula-
tory role of S. boulardii in the DCs prior to infection was related to the upregulation of tumor 
necrosis factor alpha (TNFα) and C─C chemokine receptor type 7 mRNAs, which might make 
the DCs more effective in antagonizing bacteria [64, 65]. Smith et al. reported that S. boulardii 
stimulated the production of cytokines TNFα, IL-1, IL-12, IL-6, and IL-10 in DCs and also 
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induced high levels of costimulatory molecules CD80 and CD86, thus modulated the immune 
system and led to an efficient clearing of enteropathogenic bacteria from the blood stream 
coupled with a faster cytokine response [65, 66].
Probiotics also influence intestinal epithelial cells through interaction with Toll-like receptors 
(TLRs) and downregulate the expression of NF-κB and proinflammatory cytokines [67, 68]. 
This effect is supported by the following studies: the supernatant of probiotic Faecalibacterium 
prausnitzii inhibited the NF-κB pathway in vitro and in vivo and showed protective effects 
in different models such as dinitrobenzene sulfate (DNBS)-induced colitis model and dex-
tran sodium sulfate (DSS)-induced colitis [69]; the probiotic strain L. rhamnosus GG prevented 
cytokine-induced apoptosis in intestinal epithelial cells [70]; and L. rhamnosus GR-1 reduced 
the adhesion of E. coli by promoting TLR2 and NOD1 synergism and attenuating ASC-
independent NLRP3 inflammasome activation [71].
3. Probiotic as antifungals for prevention and treatment of 
candidiasis
Candida is an opportunistic pathogen, causing mucosal infections including infections in the 
oral cavity, oropharynx, esophagus, and vagina, and potentially life-threatening systemic 
candidiasis. Candida albicans is the most common fungal pathogen in humans responsible 
for causing superficial as well as deep invasive candidiasis, which are essentially caused by 
Candida biofilms attached to body surfaces. Other Candida species such as Candida  tropicalis, 
Candida guilliermondii, Candida krusei, and Candida glabrata are less frequently isolated in 
healthy and diseased humans [72–74]. Probiotics are known to reduce Candida infection in 
different organs and are generally considered to be beneficial for overall health. They appear 
to assist the host combat the pathogen by suppressing filamentation formation and reducing 
biofilm development, the mechanism of which may be related to expression of genes associ-
ated with biofilm formation and filamentation in Candida species. In vitro and in vivo studies 
have demonstrated the role of probiotics in the prevention of Candida colonization and inva-
sive candidiasis [38, 75–86].
3.1. In vitro evidences: probiotics in prevention/treatment of Candida infections
Several in vitro studies have addressed the antifungal effects of probiotics against Candida 
isolated from the human oral cavity, GI tract, and genitourinary tract [77–81, 86, 87]. The 
probiotics that have been investigated against Candida species include Lactobacillus (e.g., 
L. rhamnosus, L. plantarum, L. fermentum, L. acidophilus, L. paracasei, L. johnsonii, and L. sali-
varius), Bifidobacterium (e.g., B. bifidum and B. infantis), Saccharomyces (e.g., S. boulardii), and 
Streptococcus (e.g., S. thermophilus). Table 3 shows candidacidal activity of probiotic strains 
in different studies. C. albicans appears to be more susceptible to the antifungal effect of 
Lactobacillus than C. pseudotropicalis [81], and the probiotics exhibited growth inhibitory activi-
ties against C. glabrata, C. krusei, and C. parapsilosis [79, 87].
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Probiotics Target pathogen Study outcome References
14 strains:
L. fermentum, L. rhamnosus, L. 
plantarum, and L. acidophilus
C. albicans and C. 
pseudotropicalis
All probiotics inhibited the growth of C. 
albicans by H
2
O
2
 production and alternative 
mechanism
[81]
S. boulardii C. albicans SC5314 S. boulardii inhibited the affecting hyphae 
formation, Candida adhesion, and biofilm 
formation by capric acid production
[87]
L. paracasei IMC 502 C. glabrata, C. krusei, 
C. parapsilosis, and C. 
tropicalis
High activity toward Candida strains except 
C. glabrata and C. tropicalis
[79]
L. plantarum ATCC 8014 and 
L. johnsonii enriched or not 
with SeNPs
C. albicans ATCC 14053 Strong inhibition of C. albicans by 
supernatant of selenium-enriched 
Lactobacillus spp.
[86]
L. acidophilus, L. rhamnosus, 
L. salivarius, B. bifidum, S. 
thermophiles, and B. infantis
C. albicans 10341 Significant inhibitory effect on biofilm 
formation and reduce viability of Candida
[80]
L. rhamnosus GR-1 and L. 
reuteri RC-14
C. albicans SC5314 Visible inhibition zones of fungal C. 
albicans by probiotic treatment; low pH 
environment caused by lactic acid and 
the H
2
O
2
 production may be anti-Candida 
factors
[77]
L. acidophilus ATCC 4356 C. albicans ATCC 18804 Reduce growth of C. albicans cells by 45.1% [78]
L. casei subsp. rhamnosus Candida spp. 80 preterm neonates with a very low birth 
weight: probiotic reduced incidence and 
intensity of enteric colonization by Candida 
spp. (RCT)
[28]
L. rhamnosus GG, L. 
rhamnosus LC705, P. 
freudenreichii subsp. 
shermanii JS
Candida spp. 276 elderly people: probiotic intervention 
reduced the risk of high yeast counts by 
75% and the prevalence of hyposalivation 
(RCT)
[76]
L. rhamnosus GR-1 and L. 
reuteri RC-14
Candida spp. 55 women: probiotics significant reduced 
vaginal discharge, itching, and/or burning 
vaginal feeling, dyspareunia, and/or 
dysuria, and reduced the presence of 
Candida spp. (RCT)
[82]
L. acidophilus, L. rhamnosus, 
B. longum, B. bifidum, S. 
boulardii, and S. thermophilus
Candida spp. 150 children (aged 3 month to 12 year) on 
broad-spectrum antibiotics for at least 48 h: 
probiotic therapy avoided a significant 
increase in the number of patients 
colonized by Candida spp., significantly 
reduced the presence of Candida in the 
urine (RCT)
[83]
L. bulgaricus, B. longum, and 
S. thermophilus
Candida spp. 65 patients with Candida-associated 
stomatitis: detection rate of Candida spp. 
was reduced in the probiotic group; 
significant relief of clinical signs and 
symptoms after probiotic administration 
(RCT)
[84]
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However, the mechanisms involved in antifungal activity of probiotics against Candida remain 
unclarified. Strus et al. found that Lactobacillus strains could inhibit the growth of C. albicans 
to a certain degree and their anticandidal activity related to H
2
O
2
 production [81]. Murzyn et 
al. reported that S. boulardii was able to secrete active compounds, mainly capric acid, reduced 
the expression of hwp1, ino1, and csh1 genes that encode virulence factors in C. albicans SC5314 
cells, and inhibited filamentation of C. albicans and its mycelial development [87]. Therefore, 
it is likely that the antimicrobial molecules, organic acids, and Н
2
О
2
 produced by probiotic 
are major factors to limit growth of fungal pathogen Candida. This idea was supported by 
the research of Köhler et al. They demonstrated that low pH environment caused by lactic 
acid and the H
2
O
2
 production of L. rhamnosus GR-1 and L. reuteri RC-14 strains played impor-
tant role in their inhibition activity to C. albicans SC5314. Moreover, L. rhamnosus GR-1 and 
L. reuteri RC-14 inhibited genes associated with C. albicans biofilm formation [87]. This result, 
together with the findings in Murzyn et al. study, shed light on a novel approach for uncov-
ering the molecular mechanisms of the probiotic effect by using gene expression and related 
technology.
3.2. In vivo evidences: probiotics in prevention/treatment of Candida infections
In vivo studies, especially RCTs, have also been performed to substantiate the antifungal activ-
ity of probiotics in humans. These studies mostly focus on the sites of oral cavity, GI tract, and 
urogenital tract, which are susceptible to Candida infections (Table 3).
The elderly are a group particularly susceptible to oral candidiasis, because of frequent usage 
of dentures, hyposalivation, and their weakened immune status. Researches by Hatakka et al. 
and Kraft-Bodi et al. have shown that the daily consumption of food with L. reuteri DSM17938, 
L. reuteri ATCC PTA 5289, and L. rhamnosus GG ATCC 53103 significantly reduced the high 
yeast counts in saliva and biofilms in the elderly [76, 85]. The removal of biofilms by the use 
of probiotics that reduce the oral burden of Candida could play a major role in preventing oral 
candidiasis in denture wearers.
For the urogenital tract, chronic vulvovaginal candidiasis (VVC) is the most common candidiasis 
disease and impacts the life quality of thousands of women around the world. Researches on the 
effect of probiotics in the treatment and prophylaxis of VVC have been performed [82]. Martinez 
et al., in an RCT involving 55 women, demonstrated that the administration of L. rhamnosus 
Probiotics Target pathogen Study outcome References
L. acidophilus, B. lactis, B. 
longum, and B. bifidum
Candida spp. 112 preterm neonates (gestational age < 37 
wk and birth weight < 2500 g): probiotics 
may reduce enteral fungal colonization and 
invasive fungal sepsis in low-birth-weight 
neonates (RCT)
[75]
L. reuteri DSM 17938 and L. 
reuteri ATCC PTA 5289
Candida spp. 215 elderly people (aged 60–102 y): 
significant reduction of Candida cells in 
saliva and plaque (RCT)
[85]
Table 3. Probiotics in prevention/treatment of Candida infections.
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GR-1 and L. reuteri RC-14 significantly reduced the presence of Candida and therefore reduced 
the vaginal discharge, itching, and/or burning vaginal feeling, dyspareunia, and/or dysuria [82].
For the GI tract, Candida species are common inhabitants of GI tract. Dysbiosis of GI tract may 
lead to candidal overgrowth and possible invasive infections, especially in infants. Hence, 
immunocompromised children, especially preterm neonates with low birth weight, have 
been the target population of a large number of studies to evaluate the prevention or/and 
treatment potentials of probiotics to Candida infections [28, 75, 83]. Manzoni et al., in an RCT 
involving 80 very low birth weight (VLBW) neonates, demonstrated that orally administered 
L. casei subsp. rhamnosus significantly reduced incidence and intensity of enteric colonization 
by Candida [28]. Another RCT, by Roy et al., found L. acidophilus, B. lactis, B. longum, and B. bifi-
dum reduced enteral fungal colonization and invasive fungal sepsis in 112 preterm neonates 
(gestational age < 37 wk and birth weight < 2500 g) [75].
Together, both the laboratory studies and clinical studies showed that probiotics could pre-
vent Candida colonization by inhibiting adhesion, filamentation, and biofilm formation, and 
therefore supplementation of probiotics could be a potential approach for reducing Candida 
colonization and invasive candidiasis.
4. Safety of probiotics
Although most commercially available probiotic strains are generally regarded as safe and 
none of the clinical studies mentioned above were reported to have adverse effects directly 
related to probiotics, there are some concerns regarding the safety of probiotics, including 
potential of bacteremia and/or endocarditis occurrence, toxicity to the gastrointestinal tract, 
and transfer of antibiotic resistance [4].
4.1. Potential of bacteremia and/or endocarditis occurrence
Lactic acid bacteria, including Bifidobacterium, have been reported to cause bacteremia as well 
as endocarditis [88–92]. Cannon et al. described that L. rhamnosus caused liver abscess, lactobac-
illemia, and infective endocarditis in a few case studies, and also the occurrence of Lactobacillus 
sepsis was directly linked with the ingestion of probiotic supplements, especially among immu-
nocompromised patients and those with endocarditis [89]. Kunz et al. found two premature 
infants with short gut syndrome developed Lactobacillus bacteremia while taking Lactobacillus 
GG supplements. However, the risk of infection due to Lactobacilli is extremely rare. Statistic 
data from surveillance in Finland suggest that there was no increase in Lactobacillus bacteremia 
during 1990–2000, and Lactobacilli were isolated in 0.02% of all blood cultures [93].
4.2. Toxicity to the gastrointestinal tract
The role of probiotics on gastrointestinal physiology suggests a theoretical possibility that the 
production of metabolites might be undesirable and also might lead to malabsorption due to 
deconjugation of bile salts. These might increase the risk of colon cancer; however, there is no 
epidemiologic or clinical evidence to support this hypothesis [94, 95].
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4.3. Transfer of antibiotic resistance
Another major safety concern of theoretical importance is genetic transfer of antibiotic resis-
tance from probiotic strains to pathogenic cells in the gastrointestinal tract [96, 97]. Plasmids 
with antibiotic-resistance genes, including genes encoding resistance to tetracycline, eryth-
romycin, chloramphenicol, and macrolide-lincosamide-streptogramin, have been found in 
L. plantarum, L. fermentum, L. acidophilus, and L. reuteri strains. L. plantarum 5057 exhibited 
tetracycline resistance, and L. lactis was with streptomycin, tetracycline, and chloramphenicol 
resistances [98–100]. Although the transfer of native Lactobacillus plasmids is quite rare, there 
are some cases, e.g., the antibiotic-resistance plasmids from Lactococcus species could transfer 
to Leuconostoc species and Pediococcus species.
With respect to the potential risks of probiotics, it is important to conduct population-based 
surveillance for safety concern.
5. Conclusions
Probiotics have the ability to restore the imbalance of intestinal microbiota and could act as 
both prophylactic and adjunctive therapy against candidiasis. Antifungal effect of probiotics 
is likely due to their interference with Candida biofilm development and hyphal differentia-
tion. Safety may be of concern in application, as probiotic strains may, although quite rarely, 
cause bacteremia, fungemia, and sepsis. Well-designed RCTs are required to address these 
issues before the routine use of probiotics is recommended.
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